Urologiia (Moscow, Russia : 1999) · 2020
[The efficacy of recombinant interferon -2b in the treat ment of male infertility caused by human papilloma- virus].
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ibishev K S, Magomedov G A, Riabenchenko N N, Mantsov A A
Аннотация
INTRODUCTION: The involvement of human papillomavirus (HPV) in male infertility is becoming increasingly evident. There are no approved treatment for male infertility associated with human papillomavirus infection (HPV).
RESEARCH OBJECTIVE: To study the effectiveness of interferon therapy (recombinant interferon -2b with an antioxidant complex of vitamins E and C) in the treatment of male infertility associated with HPV MATERIALS AND METHODS: An analysis of the results of a survey of 103 patients aged 28 to 46 years with a diagnosis of infertility associated with HPV was carried out. Ejaculate was assessed in accordance with the WHO recommendations (2010); the amplification method of DNA diagnostics, polymerase chain reaction (PCR), was used to identify the type of virus. The material for the study was ejaculate. Depending on the therapy, the patients were divided into two groups: the 1st control group (n=54) - were under observation. Group 2 (n=49) - received treatment with recombinant interferon -2b with an antioxidant complex of vitamins E and C (Viferon), (rectal suppositories), which was prescribed at a dosage of 3,000,000 IU per rectum 2 times a day with an interval of 12 hours for 20 days. The observation period is 1 year. The end point of the study was the onset of pregnancy.
RESULTS: When comparing the characteristics of the groups obtained, no statistically significant difference was found. Almost all of the studied patients had various types of pathospermia. When identifying the virus, 6, 16, 18, 31, 33 types of HPV were most often detected in the ejaculate. The most common disorder in the studied groups is asthenozoospermia. The association of several types of virus had a statistically significant weak inverse correlation with morphological changes in the ejaculate, in comparison with the ejaculate where one type of virus was detected (r=0.257, p=0.0853). The more types of the virus were registered in the ejaculate in associative relationships, the more the expression of morphological changes in the ejaculate.
CONCLUSIONS: Male infertility may be due to the presence of HPV in the ejaculate. The more types of HPV present in the ejaculate, the lower the total sperm motility. For the treatment of infertility caused by PVI, it is recommended to use recombinant interferon -2b with an antioxidant complex of vitamins E and C.
RESEARCH OBJECTIVE: To study the effectiveness of interferon therapy (recombinant interferon -2b with an antioxidant complex of vitamins E and C) in the treatment of male infertility associated with HPV MATERIALS AND METHODS: An analysis of the results of a survey of 103 patients aged 28 to 46 years with a diagnosis of infertility associated with HPV was carried out. Ejaculate was assessed in accordance with the WHO recommendations (2010); the amplification method of DNA diagnostics, polymerase chain reaction (PCR), was used to identify the type of virus. The material for the study was ejaculate. Depending on the therapy, the patients were divided into two groups: the 1st control group (n=54) - were under observation. Group 2 (n=49) - received treatment with recombinant interferon -2b with an antioxidant complex of vitamins E and C (Viferon), (rectal suppositories), which was prescribed at a dosage of 3,000,000 IU per rectum 2 times a day with an interval of 12 hours for 20 days. The observation period is 1 year. The end point of the study was the onset of pregnancy.
RESULTS: When comparing the characteristics of the groups obtained, no statistically significant difference was found. Almost all of the studied patients had various types of pathospermia. When identifying the virus, 6, 16, 18, 31, 33 types of HPV were most often detected in the ejaculate. The most common disorder in the studied groups is asthenozoospermia. The association of several types of virus had a statistically significant weak inverse correlation with morphological changes in the ejaculate, in comparison with the ejaculate where one type of virus was detected (r=0.257, p=0.0853). The more types of the virus were registered in the ejaculate in associative relationships, the more the expression of morphological changes in the ejaculate.
CONCLUSIONS: Male infertility may be due to the presence of HPV in the ejaculate. The more types of HPV present in the ejaculate, the lower the total sperm motility. For the treatment of infertility caused by PVI, it is recommended to use recombinant interferon -2b with an antioxidant complex of vitamins E and C.